Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.

Abstract

We initiated a clinical trial for patients with advanced malignant melanoma treated with an anti-idiotype antibody that mimics the disialoganglioside GD2. We report the clinical and immune responses of the first 12 patients entered into this trial. Patients received 1-, 2-, 4-, or 8-mg doses of the anti-idiotype antibody mixed with 100 microg of QS-21 adjuvant every other week, four times, and then monthly. Twelve patients have been on trial for 2-23 months, and all of them have generated immune responses. Patients were removed from the study if they demonstrated disease progression. Hyperimmune sera from all 12 patients revealed an anti-anti-idiotypic Ab3 response, as demonstrated by the inhibition of Ab2 binding to Ab1 by patients' immune sera. To further test the anti-anti-idiotypic response, patients' Ab3 antibodies were affinity purified on Sepharose 4B columns containing adsorbed immunizing anti-idiotype immunoglobulin. Purified Ab3 of all patients studied inhibited binding of Ab1 to a GD2-positive cell line. Purified Ab3 also inhibited binding of Ab1 to purified GD2, in a manner comparable to equal quantities of purified Ab1. The patient Ab3 was truly an Ab1' because it specifically bound to purified disialoganglioside GD2. The isotypic specificity of the Ab3 antibody was predominantly IgG, with only minimal IgM. The predominant IgG subclass was IgG1, with approximately equal quantities of IgG2, IgG3, and IgG4. These Ab3 antibodies reacted specifically with tumor cells expressing GD2 by immune flow cytometry and immunoperoxidase assays. Five patients' Ab3 antibodies studied for antibody-dependent cellular cytotoxicity were positive. One patient had a complete clinical response, with resolution of soft tissue disease, and six patients had stable disease, ranging from 9 to 23 months, and are being continued on vaccine therapy. Toxicity consisted of local reaction at the site of the injection, including induration and pain that generally resolved within a few days. Mild fever and chills were observed in 75% of the patients but rarely required acetaminophen. There was no additional toxicity, including abdominal pain that was previously seen with infusion of murine monoclonal anti-GD2 antibody. Current trials include patients with stage III melanoma and small cell lung cancer. Future trials will attempt to enhance the antitumor response by the addition of interleukin 2, granulocyte macrophage colony-stimulating factor, and other cytokines, together with the 1A7 vaccine.

• Authors: K A Foon, G Sen, L Hutchins, O L Kashala, R Baral, M Banerjee, M Chakraborty, J Garrison, R A Reisfeld, M Bhattacharya-Chatterjee
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 4 Issue 5 Pg. 1117-24 (May 1998) ISSN: 1078-0432 [Print] United States
• PMID: 9607568 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antibodies, Anti-Idiotypic
• Cancer Vaccines
• Gangliosides
• sialogangliosides

Topics

• Adult
• Aged
• Animals
• Antibodies, Anti-Idiotypic (administration & dosage, adverse effects)
• Cancer Vaccines (administration & dosage, adverse effects, immunology)
• Cell Count (drug effects)
• Dose-Response Relationship, Immunologic
• Female
• Gangliosides (immunology)
• Humans
• Immunotherapy
• Lymphatic Metastasis (immunology, pathology)
• Male
• Melanoma (immunology, pathology, therapy)
• Mice
• Middle Aged
• Tumor Cells, Cultured (drug effects)